Hyeong Seok Kim

Hyeong Seok Kim

Auto-generated profile, based on publicly available information

Hyeong Seok Kim

Division of Hepatobiliary-Pancreatic Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
YHYoungmin Han
Youngmin Han
HLHongeun Lee
Hongeun Lee
JKJae Seung Kang
Jae Seung Kang
JKJae Ri Kim
Jae Ri Kim
HKHyeong Seok Kim
Hyeong Seok Kim
JJJin-Young Jang
Jin-Young Jang

23 March 2022 in Advanced Functional Materials
Verified
Journal Article
Open access
SJSeong‐Min Jo
Seong‐Min Jo
HKHyeong Seok Kim
Hyeong Seok Kim
MWMiae Won
Miae Won
CCCarole Champanhac
Carole Champanhac
Jong Seung KimJong Seung Kim
Jong Seung Kim
KLKatharina Landfester
Katharina Landfester
Synergistic strategies by combining nanoreactors and prodrugs hold tremendous potential in anticancer treatment. However, precise death of target cancer cells remains a significant challenge due to the absence of an elaborate cancer targeting strategy. Here, a dual‐targeting approach that combines the action of H2O2‐producing folate receptor‐targeted nanoreactors with a cyclooxygenase‐2 (COX‐2) targeted prodrug is reported. A folate‐modified silica nanoreactor encapsulating glucose oxidase (GOX) is prepared to generate H2O2, which induces oxidative stress and allows the activation of the prodrug by targeted intracellular delivery. A novel prodrug bearing both COX‐2 targeting Celecoxib and SN‐38 anticancer agent with an H2O2‐cleavable thioketal linker to activate the drug is presented. By dual‐targeting, the generated H2O2 from GOX triggers the cleavage of a thioketal linker in the prodrug to produce the active form of the SN‐38 anticancer drug in cancer cells inducing synergistic cell death. This dual‐targeting strategy with a synergistic potency can aid in developing selective and effective anticancer therapeutics.

15 May 2021 in Gut and Liver
Verified
Journal Article
Open access
PDF file
YCYoo Jin Choi
Yoo Jin Choi
YBYoonhyeong Byun
Yoonhyeong Byun
JKJae Seung Kang
Jae Seung Kang
HKHyeong Seok Kim
Hyeong Seok Kim
YHYoungmin Han
Youngmin Han
JJJin-Young Jang
Jin-Young Jang
Yoo Jin Choi, Yoonhyeong Byun, Jae Seung Kang, Hyeong Seok Kim, Youngmin Han, Hongbeom Kim, Wooil Kwon, Do-Youn Oh, Woo Hyun Paik, Sang Hyub Lee, Ji Kon Ryu, Yong-Tae Kim, Kyungbun Lee, Haeryoung Kim, Eui Kyu Chie, and Jin-Young Jang. Gut and Liver 2021;15:466-75. https://doi.org/10.5009/gnl20070

1 January 2021 in Annals of Surgical Treatment and Research
Verified
Journal Article
Open access
PDF file
JKJae Seung Kang
Jae Seung Kang
SHSu Young Hong
Su Young Hong
YHYoungmin Han
Youngmin Han
HSHee Ju Sohn
Hee Ju Sohn
MLMirang Lee
Mirang Lee
JJJin-Young Jang
Jin-Young Jang
Kang JS, et al. Ann Surg Treat Res. 2021 Nov;101(5):266-273. https://doi.org/10.4174/astr.2021.101.5.266

22 December 2021 in BJS Open
Verified
Journal Article
Open access
PDF file
HKHyeong Seok Kim
Hyeong Seok Kim
YHYoungmin Han
Youngmin Han
JKJae Seung Kang
Jae Seung Kang
YKYoon Hyung Kang
Yoon Hyung Kang
MLMirang Lee
Mirang Lee
JJJin-Young Jang
Jin-Young Jang
Serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 have been proposed as useful preoperative biomarkers of extrahepatic bile duct cancer (EBDC). This study investigated the accuracy of CEA and CA19-9 for preoperative diagnosis of EBDC. Patients who underwent surgery for EBDC at a tertiary centre between 1995 and 2018 were studied, and those with concurrent hepatobiliary diseases (including gallbladder cancer, intraductal papillary mucinous neoplasms of pancreas), which could affect CEA or CA19-9 levels, were excluded. The control group included patients who underwent cholecystectomy for benign gallbladder diseases during the same period. Diagnostic accuracy was determined using sensitivity, specificity and area under the receiver operating characteristic curve (AUC). After excluding 23 patients, 687 patients (488 men and 199 women, mean age 65.8 years) were compared with the control group of 2310 patients. Median CEA and CA19-9 levels were 1.8 μg/l and 47.0 kU/l in patients with EBDC. CEA (cut-off 5.0 μg/l) showed AUC of 0.541, sensitivity 9.0 per cent and specificity 99.2 per cent, whereas CA19-9 (cut-off 37.0 kU/l) showed AUC of 0.753, sensitivity 56.2 per cent and specificity 94.5 per cent. Sensitivity of CA19-9 was lower in early (T stages 0–II) than advanced (T stages III and IV) cancer (47.0 versus 64.9 per cent), and also lower in N0 stage cancer than lymph node metastasis (50.1 versus 68.8 per cent). Serum CEA and CA19-9 showed low sensitivity limiting their usefulness as diagnostic biomarkers of EBDC.

22 October 2021 in The International Journal of Medical Robotics and Computer Assisted Surgery
Verified
Journal Article
Closed access
PDF file
YKYoon Hyung Kang
Yoon Hyung Kang
JKJae Seung Kang
Jae Seung Kang
YCYo Seok Cho
Yo Seok Cho
HKHyeong Seok Kim
Hyeong Seok Kim
MLMirang Lee
Mirang Lee
HLHyeon Kook Lee
Hyeon Kook Lee